Nymox Pharmaceutical
NYMX
#7601
Rank
$18.25 M
Marketcap
Bahamas
Country
$0.20
Share price
0.00%
Change (1 day)
-47.37%
Change (1 year)
Categories
P/S ratio for Nymox Pharmaceutical (NYMX)
P/S ratio as of September 2023 (TTM): N/A
According to Nymox Pharmaceutical's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2023 the company had a P/S ratio of N/A.
P/S ratio history for Nymox Pharmaceutical from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | N/A | |
| 2022 | N/A | |
| 2021 | N/A | -100% |
| 2020 | > 1000 | 2710.88% |
| 2019 | > 1000 | 380.81% |
| 2018 | 283 | -64.64% |
| 2017 | 801 | 77.82% |
| 2016 | 451 | 782.64% |
| 2015 | 51.1 | 949.65% |
| 2014 | 4.86 | -92.24% |
| 2013 | 62.7 | -16.41% |
| 2012 | 75.0 | -13.31% |
| 2011 | 86.5 | -73.88% |
| 2010 | 331 | -3.46% |
| 2009 | 343 | 43.16% |
| 2008 | 240 | -38.61% |
| 2007 | 390 | 78.39% |
| 2006 | 219 | 66.27% |
| 2005 | 132 | -40.86% |
| 2004 | 222 | -45.92% |
| 2003 | 411 | 85.29% |
| 2002 | 222 | -39.98% |
| 2001 | 370 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 4.12 | N/A | 🇺🇸 USA |
 Pfizer PFE | 2.39 | N/A | 🇺🇸 USA |
 Abbott Laboratories ABT | 4.20 | N/A | 🇺🇸 USA |
 Eli Lilly LLY | 17.8 | N/A | 🇺🇸 USA |
 Quest Diagnostics
DGX | 1.47 | N/A | 🇺🇸 USA |